| Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase … R Fleischmann, E Mysler, S Hall, AJ Kivitz, RJ Moots, Z Luo, R DeMasi, ... The Lancet 390 (10093), 457-468, 2017 | 516 | 2017 |
| Patterns of physical activity among 11 to 16 year old British children. N Armstrong, J Balding, P Gentle, B Kirby British Medical Journal 301 (6745), 203-205, 1990 | 450 | 1990 |
| Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation M Charlton, E Gane, MP Manns, RS Brown Jr, MP Curry, PY Kwo, ... Gastroenterology 148 (1), 108-117, 2015 | 414 | 2015 |
| Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir BJ Kirby, WT Symonds, BP Kearney, AA Mathias Clinical pharmacokinetics 54, 677-690, 2015 | 299 | 2015 |
| Scaling peak VO2 for differences in body size. JR Welsman, N Armstrong, AM Nevill, EM Winter, BJ Kirby Medicine and science in sports and exercise 28 (2), 259-265, 1996 | 280 | 1996 |
| Effects of pregnancy on CYP3A and P‐glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study MF Hebert, TR Easterling, B Kirby, DB Carr, ML Buchanan, T Rutherford, ... Clinical Pharmacology & Therapeutics 84 (2), 248-253, 2008 | 272 | 2008 |
| The peak oxygen uptake of British children with reference to age, sex and sexual maturity N Armstrong, J Williams, J Balding, P Gentle, B Kirby European journal of applied physiology and occupational physiology 62, 369-375, 1991 | 251 | 1991 |
| Longitudinal changes in 11‐13‐year‐olds' physical activity N Armstrong, JR Welsman, BJ Kirby Acta Paediatrica 89 (7), 775-780, 2000 | 224 | 2000 |
| Natural history of unstable angina M Fulton, W Lutz, KW Donald, BJ Kirby, B Duncan, SL Morrison, F Kerr, ... The Lancet 299 (7756), 860-865, 1972 | 224 | 1972 |
| Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry PJ Ruane, D Ain, R Stryker, R Meshrekey, M Soliman, PR Wolfe, J Riad, ... Journal of hepatology 62 (5), 1040-1046, 2015 | 202 | 2015 |
| Modeling growth and maturation changes in peak oxygen uptake in 11–13 yr olds N Armstrong, JR Welsman, AM Nevill, BJ Kirby Journal of Applied Physiology 87 (6), 2230-2236, 1999 | 154 | 1999 |
| Aerobic fitness of prepubescent children N Armstrong, BJ Kirby, AM McManus, JR Welsman Annals of human biology 22 (5), 427-441, 1995 | 154 | 1995 |
| Peak oxygen uptake and maturation in 12-yr olds. N Armstrong, JR Welsman, BJ Kirby Medicine and science in sports and exercise 30 (1), 165-169, 1998 | 152 | 1998 |
| Prognosis of new and worsening angina pectoris. B Duncan, M Fulton, SL Morrison, W Lutz, KW Donald, F Kerr, BJ Kirby, ... British Medical Journal 1 (6016), 981, 1976 | 149 | 1976 |
| Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis SM Borgia, J Dearden, EM Yoshida, SD Shafran, A Brown, Z Ben-Ari, ... Journal of hepatology 71 (4), 660-665, 2019 | 143 | 2019 |
| Cardiopulmonary fitness, physical activity patterns, and selected coronary risk factor variables in 11-to 16-year-olds N Armstrong, J Williams, J Balding, P Gentle, B Kirby Pediatric Exercise Science 3 (3), 219-228, 1991 | 137 | 1991 |
| Peak oxygen uptake and physical activity in 11-to 16-year-olds N Armstrong, J Balding, P Gentle, J Williams, B Kirby Pediatric exercise science 2 (4), 349-358, 1990 | 137 | 1990 |
| Sofosbuvir and ribavirin in adolescents 12‐17 years old with hepatitis C virus genotype 2 or 3 infection S Wirth, P Rosenthal, RP Gonzalez‐Peralta, MM Jonas, WF Balistreri, ... Hepatology 66 (4), 1102-1110, 2017 | 127 | 2017 |
| Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir BJ Kirby, AC Collier, ED Kharasch, D Whittington, KE Thummel, ... Drug metabolism and disposition 39 (6), 1070-1078, 2011 | 125 | 2011 |
| Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a SARS-CoV-2 replication inhibitor R Humeniuk, A Mathias, BJ Kirby, JD Lutz, H Cao, A Osinusi, D Babusis, ... Clinical pharmacokinetics 60, 569-583, 2021 | 123 | 2021 |
